Iovance Biotherapeutics vs Vericel
Iovance Biotherapeutics and Vericel are similar in size: $264m and $276m of revenue in their latest fiscal years. Iovance Biotherapeutics grew faster (60.6% against 16.5%). Vericel kept more of each dollar of sales as profit: a net margin of 6.0% against -148.4%.
| Latest fiscal year | Iovance BiotherapeuticsIOVA, 2025 | VericelVCEL, 2025 |
|---|---|---|
| Revenue | $264m | $276m |
| Revenue growth | 60.6% | 16.5% |
| Net income | −$391m | $16.5m |
| Operating margin | — | 4.0% |
| Net margin | -148.4% | 6.0% |
| Return on equity | -55.5% | 5.1% |
| Free cash flow | −$336m | $24.7m |
| Cash | $163m | $100m |
| Total debt | — | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 975 | 398 |
| Market value | $3.63bn | $2.07bn |
| Price vs our value range | — | — |
| Moat score | — | 32 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 33 sales |